References
- Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353–1356
- Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. An J Hematol 1990; 33: 86–89
- Alexanian R, Dimopoulos M A, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992; 80: 887–890
- Dimopoulos M A, Pouli A, Zervas K, Grigoraki V, Symeonidis A, Repoussis P, et al. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol 2003; 14: 1039–1044
- Singal S, Metha J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571
- Dimopoulos M A, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 2003; 21: 4444–4454
- Rajkumar S V, Blood E, Vesole D, Fonseca R, Greipp P R. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431
- Cavo M, Zamagni E, Tosi P, Tacchetti P, Celini C, Cangini D, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35–39
- Wu P, Davies F E, Horton C, Jenner M W, Krishnan B, Alvares C L, et al. The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to CVAMP as induction chemotherapy prior to autologous transplantation for multiple myeloma – a case-matched analysis. Leuk Lymph 2006; 47(11)2335–2338
- Jagannath S, Durie B G, Wolf J, Camacho E, Irwin D, Lutzky J, et al. Bortezomib therapy alone in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776–783
- Rajkumar S V, Hayman S R, Lacy M Q, Dispenzieri A, Geyer S M, Kabat B, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050–4053